Mandate

Vinge has advised CELLINK in a directed issue of new shares

Vinge has advised CELLINK AB (publ) in connection with a directed issue of new shares which will generate approximately MSEK 377 for CELLINK.

The subscription price was determined through an accelerated book‑building and corresponds to a discount of 3.4 per cent compared with the volume‑weighted average listed price during January on Nasdaq First North Growth Market. In addition to considerable support from existing shareholders, several new Swedish and institutional shareholders subscribed for the new issue of shares. An amount of MSEK 150 from the proceeds in relation to the new issue of shares will be used to finance the company’s organic growth plan, future operating capital requirements, etc. and the remaining proceeds can be used to finance strategic acquisitions.

Vinge’s team consisted of Anders StridEdin Agic and Anna Ståhlklo.

 

Related

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026

Vinge has advised Skeptiva AB in connection with its financing round

Skeptiva is developing the next generation of cybersecurity defenses against fraud. The company has developed an AI application that detects attacks and alerts users in real time.
March 11, 2026

Vinge has advised Main Capital in connection with the acquisition of Good Solutions Sweden AB

Good Solutions Sweden AB (”Good Solutions”) provides software that helps factories identify and reduce production losses. The software converts data from machines and operators into insights that can be used to streamline production and increase profitability.
March 11, 2026